

## Data Sharing Statement

<b>Article Info</b>	<a href="https://dx.doi.org/10.21037/tlcr-22-857">https://dx.doi.org/10.21037/tlcr-22-857</a>	
<b>Item</b>	<b>Question</b>	<b>Authors' Response (place "-" if not applicable)</b>
1	Would you like to share data collected for your study to others?	Yes.
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	Patient data after deidentification will be shared.
4	Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	Study protocol and statistical analysis plan will be shared if requested.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	Two years within the publication date, since the survival data may be updated over time.
7	To whom will you share the data?	Investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose.
8	For what type of analysis or purpose?	For analysis to evaluate the efficacy and safety of alectinib in ALK-positive non-small cell lung cancer.
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: jiangyingying678@163.com.
10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.